These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 28511189

  • 21. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
    Biró K.
    Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
    [Abstract] [Full Text] [Related]

  • 22. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
    Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O.
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Prediction of Hearing Loss Due to Cisplatin Chemoradiotherapy.
    Theunissen EA, Zuur CL, Józwiak K, Lopez-Yurda M, Hauptmann M, Rasch CR, van der Baan S, de Boer JP, Dreschler WA, Balm AJ.
    JAMA Otolaryngol Head Neck Surg; 2015 Sep; 141(9):810-5. PubMed ID: 26291150
    [Abstract] [Full Text] [Related]

  • 26. Decreased hearing after combined modality therapy for head and neck cancer.
    Pearson SE, Meyer AC, Adams GL, Ondrey FG.
    Am J Otolaryngol; 2006 Sep; 27(2):76-80. PubMed ID: 16500467
    [Abstract] [Full Text] [Related]

  • 27. Carboplatin is ototoxic.
    Kennedy IC, Fitzharris BM, Colls BM, Atkinson CH.
    Cancer Chemother Pharmacol; 1990 Sep; 26(3):232-4. PubMed ID: 2192812
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Early ototoxic changes in patients with germ cell tumor after first cycle of cisplatin-based therapy.
    Noszek L, Budai B, Prekopp P, Széchenyi R, Szőnyi M, Talpai S, Nagyiványi K, Bíró K, Géczi L.
    Laryngoscope; 2017 Aug; 127(8):E277-E282. PubMed ID: 27666741
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
    Biró K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I, Bodrogi I.
    Magy Onkol; 2006 Aug; 50(4):329-35. PubMed ID: 17216007
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Ototoxicity of cisplatin in gynaecological cancer patients.
    Laurell G, Borg E.
    Scand Audiol; 1988 Aug; 17(4):241-7. PubMed ID: 3232027
    [Abstract] [Full Text] [Related]

  • 36. Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone: A Randomized Controlled Study.
    Marshak T, Steiner M, Kaminer M, Levy L, Shupak A.
    Otolaryngol Head Neck Surg; 2014 Jun; 150(6):983-90. PubMed ID: 24618499
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin.
    Colevas AD, Lira RR, Colevas EA, Lavori PW, Chan C, Shultz DB, Chang KW.
    Head Neck; 2015 Aug; 37(8):1102-7. PubMed ID: 24737682
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.